Latest News
-

AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-

Ask the expert: Q&A on the huntingtin-lowering trial program
14 min read
In a Q&A coordinated by the UK HD Association, Dr Ed Wild answers questions on the recently-announced trial
-

Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
11 min read
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-

Switch off the genome editor when you’re done
7 min read
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
-

A new way of thinking about trials to prevent Huntington's disease
6 min read
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
-

New roles for huntingtin: removing a healthy protein to understand its function
7 min read
Completely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests.
-

Precision huntingtin-lowering drug trials target the mutant protein
10 min read
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-

A step forward for gene editing: CRISPR-Cas9 and HD
9 min read
Evolving CRISPR-Cas9 techniques can now be used to edit the HD gene in a living mouse brain.
-

Update confirms Huntington's disease 'gene silencing' trial on track
10 min read
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-

New study reveals a potential HD biomarker
8 min read
A potential HD biomarker has been uncovered in a recent clinical study

